Lynn E. Sullivan, MD Assistant Professor of Medicine Department of Internal Medicine 333 Cedar Street P.O. Box 208025 New Haven, CT 06250 Phone: 203-688-9105 Fax: 203-688-4092 e-mail: lynn.sullivan@yale.edu

Training

University of Massachusetts, Amherst, Massachusetts, B.A.
Yale University School of Medicine, New Haven, Connecticut, M.D.
Intern, Junior, and Senior Resident in Internal Medicine, Yale-New Haven Hospital, New Haven, Connecticut
Chief Resident, Yale-New Haven Hospital and West Haven Veterans Affairs Medical Center, New Haven and West Haven, Connecticut
Physician Scientist, Substance Abuse Center, Yale University School of Medicine, New Haven, Connecticut
Robert Wood Johnson Physician Faculty Scholar

Research Activities

Dr. Sullivan’s scholarly work is in the area of medical comorbidities, primarily HIV, in patients with substance use disorders. She has a specific interest in examining the integration of care for both substance use disorders and their related medical conditions and the barriers and facilitators to this integration. She is Co-Principal Investigator at the Yale site of a multi-site HRSA-funded Special Projects of National Significance (SPNS) entitled “Evaluating Methods for Integrating Buprenorphine into HIV Primary Care Settings”. She also serves as a Clinical HIV/Buprenorphine Expert to the HRSA SPNS National Evaluation and Support Center and to the 10 sites involved with this demonstration project. In addition she is focusing on optimizing substance abuse treatment in terms of its impact on HIV prevention and care. Last year, she was awarded the Robert Wood Johnson Physician Faculty Scholar Award. With funding from this award, she is evaluating the impact of buprenorphine in conjunction with different counseling interventions in order to decrease sex-related HIV risk behaviors. Dr. Sullivan has been involved with developing models of integrated care on an international level as well and has traveled to Kenya, Vietnam, and St. Petersburg, Russia in the past three years to provide guidance in this area as an international expert.

Clinical Activities

Clinic Preceptor, weekly Resident Longitudinal Clinic, Yale-New Haven Hospital Primary Care Center

Attending physician, Nathan Smith Clinic, Yale-New Haven Hospital

Selected Recent Publications

Sullivan LE, Fiellin, DA. Hepatitis C and HIV infections: implications for clinical care in injection drug users. The American Journal on Addictions. 2004; 13:1-20

Sullivan LE , Fiellin DA,Connor PG. The prevalence and impact of alcohol problems in major depression: A systematic review. The American Journal of Medicine. 2005; 118:330-341.

Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA. Decreasing international HIV transmission: The role of expanding access to opioid agonist therapies for injection drug users. Addiction.  2005; 100:150-158.

Sullivan LE, Chawarski M, O’Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment? Drug and Alcohol Dependence. 2005; 79:113-116.

Sullivan LE, Fiellin DA. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV infected patients with opioid dependence. Clinical Infectious Diseases, 2005;41(6):891-6.

Gowing LR, Farrell M, Bornemann R, Sullivan LE, Ali RL. Brief Report: Methadone treatment of injecting opioid users for prevention of HIV infection. Journal of General Internal Medicine. 2006;21:193-195.

Fiellin DA, Pantalon MV, Chawarski MC Moore BA, Sullivan LE, O’Connor PG, Schottenfeld RS. Counseling for buprenorphine-naloxone maintenance treatment in primary care. New England Journal of Medicine. 2006; 355 (4): 365-374.

Sullivan LE, Tetrault J, Bangalore D, Fiellin DA. Training HIV physicians to prescribe buprenorphine for opioid dependence. Substance Abuse. 2006; 27 (3): 11-16.

Gunderson EW, Fiellin DA, Levin FR, Sullivan LE, Kleber HD. Evaluation of a combined online and in- person training in the use of buprenorphine. Substance Abuse. 2006; 27(3): 39-45.

Sullivan LE, Bruce RD, Haltiwanger D, Lucas GE, Eldred L, Finkelstein R, Fiellin DA. Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clinical Infectious Diseases. 2006; 43: S191-196.

Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clinical Infectious Diseases. 2006; 43: S184-190.

Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV prevention. Clinical Infectious Diseases. 2006; 43: S178-183.

Berkenblit GV, Sullivan LE, Sosman JM, Gifford AL, Cofrancesco J. Update in HIV care. Journal of General Internal Medicine. 2007;22(2):253-256.

Barry DT, Moore BA, Pantalon MV, Chawarski MC, Sullivan LE, O’Connor PG, Schottenfeld RS, Fiellin DA. Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. Journal of General Internal Medicine. 2007;22(2):242-245.

Moore BA, Fiellin DA, Barry DT, Sullivan LE, Chawarski MC, O’Connor PG, Schottenfeld RS. Primary care office-based buprenorphine treatment: Comparison of heroin and prescription-opioid dependent patients. Journal of General Internal Medicine. 2007;24(4):527-530.

Gordon AJ, Sullivan LE, Alford DP, Arnsten JH, Gourevitch MN, Kertesz SG, Kunins HV, Merrill JO, Samet JH, Fiellin DA. Update in addiction medicine for the generalist. Journal of General Internal Medicine. (in press).

Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, Barry DT, O'Connor PG, Schottenfeld RS. Long-term treatment with buprenorphine/naloxone in primary care: Results at 2-5 years. American Journal on Addictions. (in press)